Cancer Patents (Class 514/19.3)
-
Patent number: 10081654Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): (I) (VI) and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.Type: GrantFiled: March 13, 2014Date of Patent: September 25, 2018Assignee: President and Fellows of Harvard CollegeInventors: Gregory L. Verdine, Gerard Hilinski
-
Patent number: 10081810Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.Type: GrantFiled: August 18, 2017Date of Patent: September 25, 2018Assignees: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Qingguo Ruan, Youhai H. Chen, Tingting Fan, Yifan Ma, Lintao Cai, Shaowen Wang, Xiaochun Wan
-
Patent number: 10072078Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: September 18, 2013Date of Patent: September 11, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
-
Patent number: 10071154Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.Type: GrantFiled: April 6, 2009Date of Patent: September 11, 2018Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David B Weiner, Matthew P Morrow
-
Patent number: 10064843Abstract: The present invention relates to a novel bis-amide derivative compound or a pharmaceutically acceptable salt thereof; a method of preparation thereof; and a pharmaceutical composition for preventing or treating diseases caused by hepatitis C virus infection and health functional food for preventing or ameliorating diseases caused by hepatitis C virus infection, containing the bis-amide derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. The novel bis-amide derivative compound of the present invention, particularly WJCPA-126, specifically binds to the catalytic site of CypA to effectively inhibit the activity of an isomerase, and the duration of the inhibitory effect can be increased because WJCPA-126 binds to CypA with high binding affinity exhibiting a low dissociation rate (Koff). Accordingly, WJCPA-126 has nontoxic and non-immunosuppressive characteristics and can effectively inhibit HCV replication in vitro and in vivo model systems.Type: GrantFiled: September 5, 2014Date of Patent: September 4, 2018Assignee: University-Industry Cooperation Group of Kyung Hee UniversityInventors: Sung Soo Kim, Won Jea Cho
-
Patent number: 10047138Abstract: Described herein are novel fusion proteins and nucleic acids encoding these fusion proteins. T cells into which such nucleic acids have been introduced are also contemplated. These T cells can express the fusion proteins on their cell surface. In various embodiments, these T cells can be used in assays to detect costimulatory ligands, inhibitors of costimulatory ligands, or inhibitors that can neutralize an inhibitor of a costimulatory ligand. Such assay methods are also described herein.Type: GrantFiled: December 2, 2015Date of Patent: August 14, 2018Assignee: AMGEN INC.Inventor: Christian Vettermann
-
Patent number: 10010541Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.Type: GrantFiled: January 29, 2015Date of Patent: July 3, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chaitan Khosla, Thomas DiRaimondo, Cornelius Kloeck
-
Patent number: 9999655Abstract: Pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells are described. In some aspects, administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.Type: GrantFiled: March 10, 2016Date of Patent: June 19, 2018Assignee: Moerae Matrix, Inc.Inventors: Cynthia Lander, Colleen Brophy, Caryn Peterson, Andrew Luber
-
Patent number: 9980956Abstract: Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an Immune Response Modifier Compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds.Type: GrantFiled: July 31, 2015Date of Patent: May 29, 2018Assignees: 3M INNOVATIVE PROPERTIES COMPANY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: John Vasilakos, Willem Overwijk
-
Patent number: 9975885Abstract: This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.Type: GrantFiled: April 28, 2017Date of Patent: May 22, 2018Assignee: PURDUE RESEARCH FOUNDATIONInventors: Sarah Emma St. John, Andrew D. Mesecar
-
Patent number: 9962424Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.Type: GrantFiled: October 15, 2015Date of Patent: May 8, 2018Assignee: LANTMÄNNEN AS-FAKTOR ABInventors: Eva Jennische, Stefan Lange, Hans-Arne Hansson
-
Patent number: 9962425Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.Type: GrantFiled: April 30, 2014Date of Patent: May 8, 2018Assignee: Korea University Research and Business FoundationInventors: Je Sang Ko, Jeong-Han Kim
-
Patent number: 9957292Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.Type: GrantFiled: December 4, 2015Date of Patent: May 1, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
-
Patent number: 9944975Abstract: Disclosed herein are hybridization buffer compositions and hybridization compositions, methods of making the compositions, and methods of using the compositions, such as the hybridization of DNA or RNA sequences by fluorescence in situ hybridization (“FISH”) and blot hybridization methodologies.Type: GrantFiled: September 2, 2016Date of Patent: April 17, 2018Assignee: Abbott Molecular Inc.Inventor: Kimberly A. Wilber-Mader
-
Patent number: 9944918Abstract: Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).Type: GrantFiled: March 15, 2016Date of Patent: April 17, 2018Assignee: The United States of America, as represented by the Secretary, Dept. of Health & Human ServicesInventors: Charles P. Venditti, Randy J. Chandler
-
Patent number: 9932386Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.Type: GrantFiled: April 19, 2012Date of Patent: April 3, 2018Assignee: Acceleron Pharma, Inc.Inventors: Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
-
Patent number: 9895423Abstract: Stabilized pharmaceutical formulations of insulin aspart are disclosed.Type: GrantFiled: January 8, 2015Date of Patent: February 20, 2018Assignee: SANOFIInventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold
-
Patent number: 9891231Abstract: The invention provides, in part, methods for diagnosing a pancreatic ?-cell disorder, predicting a subject's risk of developing a pancreatic ?-cell disorder, monitoring pancreatic ?-cell function or pancreatic ?-cell mass in a subject at risk of developing a pancreatic ?-cell disorder, monitoring efficacy of a treatment of a pancreatic ?-cell disorder in a subject, identifying a subject having an increased risk of developing a pancreatic ?-cell disorder, selecting a subject for treatment of a pancreatic ?-cell disorder, selecting a subject for participation in a clinical study, and detecting endoplasmic reticulum stress in a pancreatic ?-cell. These methods include determining at least one level of soluble mesencephalic astrocyte-derived neurotrophic factor (MANF) in a biological sample from the subject. Also provided are pharmaceutical compositions containing a soluble MANF protein and kits containing an antibody or an antigen-binding antibod fragment that binds specifically to a soluble MANF.Type: GrantFiled: January 23, 2013Date of Patent: February 13, 2018Assignee: University of MassachusettsInventors: Fumihiko Urano, Kohsuke Kanekura
-
Patent number: 9879081Abstract: A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; and a linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region and a second heavy chain antigen-binding region, and the linker connects the C-terminal of the first polypeptide and the N-terminal of the second polypeptide, and comprises a tag including a cleavable amino acid sequence at one terminal or both terminals of the linker; as well as a bispecific antibody derived from the protein complex, and related compositions and methods.Type: GrantFiled: June 25, 2014Date of Patent: January 30, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Hye Young Suh, Jae Il Lee, Su-Jeong Hwang
-
Patent number: 9873726Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: July 14, 2016Date of Patent: January 23, 2018Assignee: ONCOMED PHARMACEUTICALS, INC.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Patent number: 9815901Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.Type: GrantFiled: August 19, 2015Date of Patent: November 14, 2017Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
-
Patent number: 9796757Abstract: A peptide, derivative or peptidomimetic that blocks binding of GNA12 to ?SNAP is provided as are methods of using the same to inhibit thrombin-induced von Willebrand Factor secretion and prevent or treat thrombosis.Type: GrantFiled: April 18, 2014Date of Patent: October 24, 2017Assignee: The Board of Trustees of the University of IllinoisInventors: Richard D. Minshall, Luiza Rusu
-
Patent number: 9783585Abstract: The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces. In particular embodiments, the present invention provides nucleic acids and amino acid sequences useful for improving/increasing protein expression on the cell surface. In several embodiments, the sequences are operably linked to the N-terminal end of the protein of interest. The nucleic acid sequence encoding the sequence tag and the protein comprise part of an expression vector. The protein is expressed with the N-terminal sequence tag. In certain embodiments, the sequences of the present invention can be used with one or more chaperone or accessory proteins. In particular embodiments, the one or more chaperone/accessory proteins are encoded by the same vector or separate vectors.Type: GrantFiled: September 26, 2013Date of Patent: October 10, 2017Assignee: JOHNS HOPKINS UNIVERSITYInventors: Jennifer Pluznick, Niranjana Natarajan, Blythe Shepard
-
Patent number: 9758835Abstract: Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.Type: GrantFiled: March 13, 2014Date of Patent: September 12, 2017Assignee: Baylor Research InstituteInventors: Ajay Goel, Yuji Toiyama, C. Richard Boland, Yoshinaga Okugawa
-
Patent number: 9732158Abstract: The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.Type: GrantFiled: February 25, 2014Date of Patent: August 15, 2017Assignee: NMDX, LLCInventor: Patrick J. Muraca
-
Patent number: 9644185Abstract: A method of preparing a reprogramming induced pluripotent stem cell from a human-derived somatic cell using a fusion protein in which a reprogramming inducing factor and cell permeable peptide (CPP) are fused, and a fusion protein in which a reprogramming inducing factor and a cell permeable peptide are fused are disclosed. According to the present invention, the induced pluripotent stem cell having high efficiency and high stability can be prepared by maximizing the effect of the reprogramming inducing transcription factor beyond the existing viral peptide transporter, in inducing the reprogramming of the somatic cell.Type: GrantFiled: August 27, 2014Date of Patent: May 9, 2017Assignees: SNU R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD.Inventors: Yoon Jeong Park, Gene Lee, Hyun Nam, Jin Sook Suh, Chong-Pyoung Chung, Jue-Yeon Lee
-
Patent number: 9637518Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.Type: GrantFiled: July 10, 2014Date of Patent: May 2, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Kyoung S. Kim, Liping Zhang, Erik M. Stang
-
Patent number: 9574012Abstract: Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis.Type: GrantFiled: July 5, 2012Date of Patent: February 21, 2017Assignees: Sanofi (China) Investment Co., Ltd. Shanghai Branch, Shanghai Jiao Tong UniversityInventors: Dawei Li, Zhenghua Wu, Hao Guo, Qi Zhu, Dhahiri S. Mashausi
-
Patent number: 9567566Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.Type: GrantFiled: June 26, 2012Date of Patent: February 14, 2017Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: De Yang, Joost J. Oppenheim, Michael Bustin
-
Patent number: 9561265Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.Type: GrantFiled: July 9, 2013Date of Patent: February 7, 2017Assignee: OncoTherapy Science, Inc.Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
-
Patent number: 9556214Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.Type: GrantFiled: December 19, 2013Date of Patent: January 31, 2017Assignee: PLACON THERAPEUTICS, INC.Inventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danille N. Rockwood, Rajesh Shinde, Patrick Lim Soo, Benoît Moreau
-
Patent number: 9555126Abstract: An anti-CD19 maytansinoid immunoconjugate is used for treating B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.Type: GrantFiled: May 16, 2012Date of Patent: January 31, 2017Assignee: SanofiInventor: Rodica Morariu
-
Patent number: 9546201Abstract: Peptides from the Mucin 1 (MUC1) cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.Type: GrantFiled: February 12, 2015Date of Patent: January 17, 2017Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLCInventors: Donald W. Kufe, Surender Kharbanda
-
Patent number: 9522978Abstract: To provide a safe and stable medicine useful for prevention and treatment of prostate cancer. A novel PI polyamide is acquired that recognizes and binds to a specific base sequence of an Oct1 gene binding sequence present in a transcriptional regulatory region (AR response region) of an ACSL3 gene and regulating the transcription activity of AR. This leads to the provision of an ACSL3 gene expression inhibitor and a preventive and/or therapeutic agent of prostate cancer containing the PI polyamide as an active ingredient.Type: GrantFiled: March 11, 2014Date of Patent: December 20, 2016Assignee: NIHON UNIVERSITYInventors: Daisuke Obinata, Satoru Takahashi, Kyoko Fujiwara, Satoshi Inoue, Kenichi Takayama
-
Patent number: 9522190Abstract: Disclosed are a polymeric drug carrier-containing pharmaceutical composition with enhanced stability in its solution state and a method for stabilizing the same. More particularly, disclosed are a pharmaceutical aqueous solution composition for storage under refrigeration containing a polymeric drug carrier comprising an amphiphilic block copolymer comprised of a hydrophilic block and a hydrophobic block, and a polylactic acid derivative fixed with a di- or tri-valent metal ion at its terminal carboxyl group and having preservation stability for at least 6 months, preferably at least 12 months when stored under refrigeration, and a method for stabilizing the same.Type: GrantFiled: December 7, 2012Date of Patent: December 20, 2016Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATIONInventors: Sa-Won Lee, Joong-Woong Cho, Gyeong-Hae Kim, Min-Hyo Seo
-
Patent number: 9511150Abstract: The invention provides novel chemical entities based on sugar alcohols. These new chemical entities are biocompatible and biodegradable. The molecules can be made in a single and pure form. The molecular weights of these molecules range from small (<1000 Da) to large (1000-120,000 Da). The sugar alcohol-based molecules can have functional groups throughout the molecule for crosslinking compounds, such as the preparation of antibody-drug conjugates, or to facilitate the delivery of therapeutic proteins, peptides, siRNA, and chemotherapeutic drugs. Also provided are new conjugate entities prepared through sugar alcohol molecules. Methods of synthesizing sugar alcohol-based molecules and conjugates are also within the scope of the invention.Type: GrantFiled: January 15, 2014Date of Patent: December 6, 2016Assignee: CellMosaic, Inc.Inventor: Yumei Huang
-
Patent number: 9504737Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).Type: GrantFiled: October 23, 2008Date of Patent: November 29, 2016Assignee: TORAY INDUSTRIES, INC.Inventors: Masaki Ishibashi, Fumiyoshi Okano
-
Patent number: 9499787Abstract: The present invention relates to a method for differentiating stem cells into neurons, and is characterized in that stem cells are treated with a culture additive comprising lipoic acid, albumin, hydrocortisone, and insulin after culturing for differentiation into neurons. Since the neurons produced according to the method for producing neurons of the present invention express nestin, neuroD1, neuron-specific enolase (NSE), neurofilament (NF), tau, microtubule-associated protein 2 (MAP2), and doublecortin (DCX), just as normal mature neurons do, the neurons of the present invention can be effectively used in various therapeutic agents for neurons and as cell origins for an in vitro study system.Type: GrantFiled: February 5, 2013Date of Patent: November 22, 2016Assignee: Dongguk University Industry—Academic Cooperation FoundationInventors: Jung Keug Park, Hee Hoon Yoon, Soo Yeon Kim, Young Kwon Seo
-
Patent number: 9493747Abstract: Disclosed herein are methods and compositions related to engineered fragments of the human transglutaminase-related protein family, described herein as engineered transglutaminase barrel proteins (ETBPs), that have utility as high affinity, high selectivity target-binding proteins offering advantages as antibody equivalents for therapeutic, analytical, manufacturing and research purposes. ETBPs differ from naturally occurring human transglutaminase fragments by the addition, deletion, replacement and/or substitution of the naturally occurring amino acid sequence. ETBPs can be easily expressed in prokaryotic cells and in many cases can be purified by a simple solubilization and precipitation method.Type: GrantFiled: January 5, 2009Date of Patent: November 15, 2016Assignee: The General Hospital CorporationInventors: Elena V. Getmanova, Alexander Kovtun, Lin Sun, Edward Fritsch, Brian Seed
-
Patent number: 9433577Abstract: The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition.Type: GrantFiled: December 6, 2010Date of Patent: September 6, 2016Assignee: Merck Patent GmbHInventor: Marcus Eber
-
Patent number: 9421239Abstract: A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.Type: GrantFiled: May 22, 2015Date of Patent: August 23, 2016Assignee: TRUSTEES OF DARTMOUTH COLLEGEInventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguérin, Rudolf Volkmer, Lars Vouilleme
-
Patent number: 9416383Abstract: Methods for enhancing a biological activity, for example, catalytic activity, of a lipase, are provided. In some embodiments, the methods include the step of alkylating one or more cysteine residues present within the lipase. Also provided are modified polypeptides for which a biological activity is enhanced by the disclosed methods, methods for using the disclosed polypeptides, including for the transesterification of renewable oils to produce a biofuel, and cell free systems that include a lipase, to which one or more moieties, such as steroidal moieties, are conjugated.Type: GrantFiled: April 28, 2008Date of Patent: August 16, 2016Assignee: University of North Carolina at Chapel HillInventors: Dhiren R. Thakker, Ryan R. Klein
-
Patent number: 9416192Abstract: The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.Type: GrantFiled: August 5, 2009Date of Patent: August 16, 2016Assignee: TORAY INDUSTRIES, INC.Inventors: Fumiyoshi Okano, Takayoshi Ido, Takanori Saito, Shinichi Kobayashi
-
Patent number: 9409888Abstract: Disclosed are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein Z, X, Q and R1 are as described in this application, and methods of using the compounds in the treatment of cancer.Type: GrantFiled: December 9, 2013Date of Patent: August 9, 2016Assignee: Hoffmann-La Roche Inc.Inventor: Steven Gregory Mischke
-
Patent number: 9410943Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.Type: GrantFiled: March 13, 2014Date of Patent: August 9, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Cigall Kadoch, Gerald R. Crabtree
-
Patent number: 9402358Abstract: This invention relates in part to plant breeding and herbicide tolerant plants. This invention includes a novel aad-1 transformation event in corn plants comprising a polynucleotide sequence, as described herein, inserted into a specific site within the genome of a corn cell. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits, including, for example, other herbicide tolerance gene(s) and/or insect-inhibitory proteins. Additionally, the subject invention provides assays for detecting the presence of the subject event in a sample (of corn grain, for example). The assays can be based on the DNA sequence of the recombinant construct, inserted into the corn genome, and on the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are also provided.Type: GrantFiled: August 18, 2010Date of Patent: August 2, 2016Assignee: Dow AgroSciences LLCInventors: Yunxing C. Cui, Jill R. Bryan, Donald G. Maum, Gregory J. Gilles, Terry R. Wright, Jennifer L. Hamilton, Nicole L. Arnold, Nathan J. VanOpdorp, Tina M. Kaiser, Ning Zhou
-
Patent number: 9382540Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.Type: GrantFiled: May 1, 2015Date of Patent: July 5, 2016Assignee: Isis Pharmaceuticals, IncInventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
-
Patent number: 9358252Abstract: Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.Type: GrantFiled: September 27, 2013Date of Patent: June 7, 2016Assignee: MOMENTA PHARMACEUTICALS, INC.Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
-
Patent number: 9353350Abstract: This invention provides a multipolar cell including three or more centrosomes dispersed therein and a multipolar spindle formed so as to extend from the three or more respective centrosomes. The multipolar cell production method provided by the present invention supplies cultured eukaryotic cells with a synthetic peptide as a multipolarity-inducing peptide, with the synthetic peptide having an amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 12 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the selected amino acid sequence.Type: GrantFiled: December 20, 2012Date of Patent: May 31, 2016Assignee: TOAGOSEI CO. LTD.Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida, Yuki Kobayashi
-
Patent number: 9353351Abstract: This invention provides a multipolar cell including three or more centrosomes dispersed therein and a multipolar spindle formed so as to extend from the three or more respective centrosomes. The multipolar cell production method provided by the present invention supplies cultured eukaryotic cells with a synthetic peptide as a multipolarity-inducing peptide, with the synthetic peptide having an amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 10 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the selected amino acid sequence. As the eukaryotic cells, cultured tumor cells are used.Type: GrantFiled: December 20, 2012Date of Patent: May 31, 2016Assignee: TOAGOSEI CO. LTD.Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida, Yuki Kobayashi